Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases

• US 20090123367A1
• Filed: 02/23/2006
• Published: 05/14/2009
• Est. Priority Date: 03/05/2003
• Status: Abandoned Application

• Current Assignee: Halozyme, Inc. (Halozyme Therapeutics, Inc.)
• Original Assignee: DelfMEMS Co.
• Inventors: Keller, Gilbert A., Haller, Michael F., Dylan, Tyler M., Frost, Gregory I., Kundu, Anirban, Bookbinder, Louis H.
• Application Number:
  US11/884,862
• Publication Number:
  US 20090123367A1
• Time in Patent Office: Days
• US Class Current: 424/1.490
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 9/2408 acting on alpha -1,4-glucosidic bonds

Abstract

The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Claims

1. A substantially purified glycoprotein, comprising a neutral active soluble hyaluronidase polypeptide and at least one N-linked sugar moiety, wherein the N-linked sugar moiety is covalently attached to an asparagine residue of the polypeptide.

120. The polypeptide of claim 1, wherein the polymer is PEG.

121. The polypeptide of claim 120, wherein the polypeptide comprises at least about three PEG moieties per polypeptide.

122. The polypeptide of claim 120, wherein said PEG moieties are branched.

123. The polypeptide of claim 120, wherein said PEG moieties are selected from the group consisting of mPEG-SBA (5 kDa), mPEG-SBA (20 kDa), MPEG-SBA 30 kDa), mPEG-SMB (20 kDa) mPEG-SMB (30 kDa), mPEG-butyraldehyde (30 kDa), MPEG-SPA (20 kDa), MPEG-SPA (30 kDa), mPEG2-NHS (10 kDa branched), mPEG2-NHS (20 kDa branched), mPEG-NHS (40 kDa branched), mPEG2-NHS (60 kDa branched), PEG-NHS-biotin (5 kDa biotinylated), PEG-p-nitrophenyl-carbonate (30 kDa) and PEG-propionaldehyde (30 kDa).

2-12. -12. (canceled)

13. A polypeptide, consisting essentially of a hyaluronidase domain or a catalytically active portion thereof of a human hyaluronidase protein.

154. The polypeptide of claim 13, wherein the polymer is PEG.

155. The polypeptide of claim 154, wherein the polypeptide comprises at least about three PEG moieties per polypeptide.

156. The polypeptide of claim 154, wherein said PEG moieties are branched.

157. The polypeptide of claim 154, wherein said PEG moieties are selected from the group consisting of mPEG-SBA (5 kDa), mPEG-SBA (20 kDa), mPEG-SBA 30 kDa), mPEG-SMB (20 kDa) MPEG-SMB (30 kDa), mPEG-butyraldehyde (30 kDa), MPEG-SPA (20 kDa), mPEG-SPA (30 kDa), mPEG2-NHS (10 kDa branched), mPEG2-NHS (20 kDa branched), mPEG-NHS (40 kDa branched), mPEG2-NHS (60 kDa branched), PEG-NHS-biotin (5 kDa biotinylated), PEG-p-nitrophenyl-carbonate (30 kDa) and PEG-propionaldehyde (30 kDa).

14-79. -79. (canceled)

80. A method of promoting delivery of a sHASEGP or other glycosaminoglycanase (GAG Enzyme) into a first tissue within a mammal, comprising introducing a volume of liquid comprising the GAG Enzyme into the first tissue and allowing the volume of liquid and catalytic activity of the GAG Enzyme to promote delivery of the GAG Enzyme into the tissue.

81. The method of claim 80, wherein the volume of liquid is sufficient to cause localized distension of the first tissue at or near the site of introduction of the volume of liquid.

82. The method of claim 80, further comprising introducing one or more additional pharmacologic or other agents (A-X) into the first tissue.

83. The method of claim 82, wherein A-X is selected from the group consisting of a detectable molecule or other diagnostic agent, an anesthetic or other tissue-modifying agent, a pharmacologic or pharmaceutically effective agent, and a cosmetic or other esthetic agent.

84. The method of claim 82, wherein A-X is a pharmacologic or pharmaceutically effective agent.

85. The method of claim 82, wherein A-X is selected from the group consisting of a chemotherapeutic or anticancer agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonocidal agent, an anti-parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, an antiarthritics agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasitic agent, an antihistamine agent, an alpha-adrenargic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a bacteriostatic agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a cosmetic or esthetic agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, an electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sleep inducer, a sympathomimetic agent, a tranquilizer agent, a urinary agent, a vaginal agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, or an angiotensin converting enzyme inhibitor agent.

86. The method of claim 82, wherein A-X is selected from the group consisting of Adalimumabs (e.g. Humira™

), Agalsidase Betas (e.g. Fabrazyme™

), Aldesleukins (PROLEUKIN™

IL-2), Alefacepts (e.g. Amevive™

), Ampicillins (e.g. UNASYN™

Injection), Anakinras (e.g. Kineret™

), Antipoliomyelitic Vaccines (e.g. PEDIARIX™

), Anti-Thymocytes (e.g. THYMOGLOBULIN™

), Azithromycins (e.g. Zithromax™

IV), Becaplermins (e.g. Regranex™

), Caspofungins (e.g. Cancidas™

), Cefazolins (e.g. ANCEF™ and

CEFAZOLIN™

), Cefepimes (e.g. Maxipime™

), Cefotetans (e.g. CEFOTAN™

), Ceftazidimes (e.g. FORTAZ™

), Ceftriaxones (e.g. Rocefin™

), Cetuximabs (e.g. Erbitux™

), Cilastatins (e.g. Primaxin™

IV), Clavulanic Acids (e.g. in conjunction with Amoxicillins such as in AUGMENTIN™

), Clindamycins (e.g. CLEOCIN™

), Darbepoetin Alfas (e.g. Aranesp™

), Deaclizumabs (e.g. Zenapax™

), Diphtheria Toxoids (typically in combinations e.g. DAPTACEL™

, Infanrix™ and

PEDIARIX™

), Efalizumabs (e.g. Raptiva™

), Epinephrines (e.g. EPIPEN™

), Erythropoietin Alphas (e.g. Epogen™

And Procrit™

), Etanercepts (e.g. Enbrel™

), Filgrastims (e.g. Neupogen™

), Fluconazoles (e.g. DIFLUCAN™

Injection), Follicle-Stimulating Hormones such as Follitropin Alphas (e.g. GONAL-F™

) and Follitropin Betas (e.g. Follistim™

), Fosphenyloins (e.g. CEREBYX™

), Fluconazoles (e.g. Diflucan™

), Gadodiamides (e.g. OMNISCAN™

), Gadopentetates (e.g. MAGNEVIST™

), Gatifloxacins (e.g. Tequin™

), Glatiramers (e.g. Copaxone™

), GM-CSF'"'"'s (e.g. Leukine™

), Goserelins (e.g. Zoladex™

), Granisetrons (e.g. Kytril™

), Haemophilus Influenza B'"'"'s (e.g. COMVAX™ and

HibTITER™

), Haloperidols (e.g. HALDOL™

), Hepatitis A Vaccines (e.g. HAVRIX™

, TWINRIX™ and

VAQTA™

), Hepatitis B Vaccines (e.g. recombinants COMVAX™

, ENGERIX™

-B, RECOMBIVAX™

-HB, TWINRIX™

, and non-recombinants BAYHEP™

-B and NABI™

-HB), Ibritumomab Tiuxetans (e.g. Zevalin™

), Immunoglobulins (including mixtures of immunoglobulins such as GAMMAGARD™ and

the like, as well as any of a variety of purified immunoglobulins), Influenza Virus Vaccines (e.g. FLUMIST™

), Infliximabs (e.g. Remicade™

), Insulins (e.g. HUMALOG™

, HUMALOG™

MIX 75/25™

, HUMULIN™

products (incl. 50/50, 70/30, Regular, NPH, Ultra and Ultralente), and NOVOLIN™

), Insulin Glargines (e.g. Lantus™

), Interferon Alfa-2a'"'"'s (ROFERAN™

-A), Interferon Alfa-2b'"'"'s (e.g. Intron-A™

), Interferon Alfacon-1'"'"'s (e.g. INFERGEN™

), Interferon Alfa-n3s (e.g. ALFERON N™

), Interferon Betas (e.g. Betaseron™

And Betaferon™

), Interferon Beta-1a'"'"'s (e.g. Avonex™

And Rebif™

), Interferon Gammas (e.g. ACTIMMUNE™

), Iodixanols (e.g. VISIPAQUE™

), Iohexyls (OMNIPAQUE™

), Iopamidols, Ioversols (e.g. OPTIRAY™

), Ketorolacs (e.g. TORADOL™

), Laronidases (e.g. Aldurazyme™

), Levofloxacins (e.g. Levaquin™

), Lidocaines, Linezolids (e.g. ZYVOX™

), Lorazepams (e.g. ATIVAN™

), Measles Vaccines (e.g. ATTENUVAX™

), Measles-Mumps-Rubella Virus Vaccines (e.g. M-M-R™

II), Medroxyprogesterones (e.g. Depo-Provera™

), Meropenems (e.g. MERREM™

IV), Methylprednisolones (e.g. Solu-Medrol™

), Midazolams (e.g. VERSED™

), Morphines (e.g. ASTRAMORPH/PF™

), Octreotides (e.g. Sandostatin™

), Omalizumabs (e.g. Xolair™

), Ondansetrons (e.g. Zofran™

), Palivizumabs (e.g. Synagis™

), Pantoprazoles (e.g. Protonix™

), Pegaspargases (e.g. ONCASPAR™

), Pegfilgrastims (e.g. Neulasta™

), Peg-Interferon Alfa-2a'"'"'s (e.g. PegASYS™

), Peg-Interferon Alfa-2b'"'"'s (e.g. Peg-Intron™

), Pegvisomants (e.g. SOMAVERT™

), Pertussis vaccines, Piperacillins (e.g. Zosyn™

), Pneumococcal Vaccines (e.g. PNEUMOVAX™

     23) and Pneumococcal Conjugate Vaccines (e.g. PREVNAR™

), Promethazines (e.g. Phenergan™

), Reteplases (e.g. Retavase™

), Somatropins (e.g. GENOTROPIN™

, HUMATROPE™

, NORDITROPIN™

, NUTROPIN™

, SAIZEN™

, SEROSTIM™

, ZORBTIVE™

), Sulbactams, Sumatriptans (e.g. Imitrex™

), Tazobactams, Tenecteplases (e.g. Tnkase™

), Tetanus Purified Toxoids, Ticarcillins (e.g. TIMENTIN™

), Tositumomabs (e.g. Bexxar™

), Triamcinolone Acetonides, Vancomycins (e.g. Vancocin™

), Varicella vaccines (e.g. VARIVAX™

), and other vaccines.

87. The method of claim 82, wherein A-X is an antibiotic agent or combination of agents selected from the group consisting of Aminoglycosides;

Amphenicols;

Ansamycins;

Carbacephems;

Carbapenems;

Cephalosporins or Cephems;

Cephamycins;

Clavams;

Cyclic lipopeptides;

Diaminopyrimidines;

Ketolides;

Lincosamides;

Macrolides;

Monobactams;

Nitrofurans;

Oxacephems;

Oxazolidinones;

Penems, thienamycins and miscellaneous beta-lactams;

Penicillins;

Polypeptides antibiotics;

Quinolones;

Sulfonamides;

Sulfones;

Tetracyclines; and

other antibiotics (such as Clofoctols, Fusidic acids, Hexedines, Methenamines, Nitrofurantoins Nitroxolines, Ritipenems, Taurolidines, Xibomols).

88. The method of claim 80, wherein the GAG Enzyme is a sHASEGP.

89. The method of claim 88, wherein the sHASEGP is a human sHASEGP.

90. The method of claim 89, wherein the human sHASEGP is a PH20 sHASEGP.

91. The method of claim 90, wherein the sHASEGP is a soluble polypeptide as set forth in SEQ ID NO. 4.

92. The method of claim 88, wherein the sHASEGP is a pegylated or super-sialated sHASEGP.

93. The method of claim 91, wherein the sHASEGP is a pegylated human PH20 sHASEGP.

94. A method of increasing the permeability of a target tissue of a mammal, comprising introducing a sHASEGP into the tissue.

95. The method of claim 94, wherein the sHASEGP is introduced into the tissue by injection of the sHASEGP into the tissue or into a nearby tissue.

96. The method of claim 94, wherein the sHASEGP is introduced into the tissue by prior introduction of the sHASEGP into the bloodstream supplying the tissue.

97. The method of claim 96, wherein the prior introduction into the bloodstream is mediated by intravenous injection or infusion of the sHASEGP.

98. The method of claim 96, wherein the prior introduction into the bloodstream is mediated by non-intravenous parenteral administration of the sHASEGP.

99. The method of claim 94, further comprising introducing A-X into the tissue.

100. The method of claim 99, wherein A-X is introduced into the tissue by injection into the tissue or into a nearby tissue.

101. The method of claim 99, wherein A-X is introduced into the tissue by prior introduction of the PH20 into the bloodstream supplying the tissue.

102. The method of claim 101, wherein the prior introduction into the bloodstream is mediated by intravenous injection or infusion of the molecule or macromolecular complex.

103. The method of claim 101, wherein the prior introduction into the bloodstream is mediated by non-intravenous parenteral administration of the molecule or macromolecular complex.

104. The method of claim 99, wherein the step of introducing A-X into the tissue is initiated within three hours following the step of introducing the sHASEGP into the tissue.

105. The method of claim 99, wherein the step of introducing A-X into the tissue is initiated within twelve hours following the step of introducing the sHASEGP into the first tissue.

106. The method of claim 99, wherein A-X is a molecule selected from the group consisting of a small molecule, a protein, and a nucleic acid.

107. The method of claim 99, wherein A-X is a macromolecular complex comprising combinations of molecules selected from the group consisting of small molecules, proteins, nucleic acids, lipids and amphiphilic molecules.

108. The method of claim 99, wherein A-X is selected from the group consisting of a detectable molecule or other diagnostic agent, an anesthetic or other tissue-modifying agent, a pharmacologic or pharmaceutically effective agent, and a cosmetic or other esthetic agent.

109. The method of claim 99, wherein A-X is a pharmacologic or pharmaceutically effective agent.

110. The method of claim 99, wherein A-X is selected from the group consisting of a chemotherapeutic or anticancer agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonocidal agent, an anti-parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, an antiarthritics agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasitic agent, an antihistamine agent, an alpha-adrenargic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a bacteriostatic agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a cosmetic or esthetic agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, an electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sleep inducer, a sympathomimetic agent, a tranquilizer agent, a urinary agent, a vaginal agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, or an angiotensin converting enzyme inhibitor agent.

111. The method of claim 99, wherein A-X is an anticancer agent or combination of agents selected from the group consisting of Aclacinomycins, Actinomycins, Adriamycins, Ancitabines, Anthramycins, Azacitidines, Azaserines, 6-Azauridines, Bisantrenes, Bleomycins, Cactinomycins, Carmofurs, Carmustines, Carubicins, Carzinophilins, Chromomycins, Cisplatins, Cladribines, Cytarabines, Dactinomycins, Daunorubicins, Denopterins, 6-Diazo-5-Oxo-L-Norleucines, Doxifluridines, Doxorubicins, Edatrexates, Emitefurs, Enocitabines, Fepirubicins, Fludarabines, Fluorouracils, Gemcitabines, Idarubicins, Loxuridines, Menogarils, 6-Mercaptopurines, Methotrexates, Mithramycins, Mitomycins, Mycophenolic Acids, Nogalamycins, Olivomycines, Peplomycins, Pirarubicins, Piritrexims, Plicamycins, Porfiromycins, Pteropterins, Puromycins, Retinoic Acids, Streptonigrins, Streptozocins, Tagafurs, Tamoxifens, Thiamiprines, Thioguanines, Triamcinolones, Trimetrexates, Tubercidins, Vinblastines, Vincristines, Zinostatins, And Zorubicins.

112. The method of claim 99, wherein A-X is an antibody or other protein having anti-cancer or chemotherapeutic activity.

113. The method of claim 99, wherein A-X is an antibiotic agent or combination of agents selected from the group consisting of Aminoglycosides;

Amphenicols;

Ansamycins;

Carbacephems;

Carbapenems;

Cephalosporins or Cephems;

Cephamycins;

Clavams;

Cyclic lipopeptides;

Diaminopyrimidines;

Ketolides;

Lincosamides;

Macrolides;

Monobactams;

Nitrofurans;

Oxacephems;

Oxazolidinones;

Penems, thienamycins and miscellaneous beta-lactams;

Penicillins;

Polypeptides antibiotics;

Quinolones;

Sulfonamides;

Sulfones;

Tetracyclines; and

other antibiotics (such as Clofoctols, Fusidic acids, Hexedines, Methenamines, Nitrofurantoins Nitroxolines, Ritipenems, Taurolidines, Xibomols).

114. The method of claim 94, wherein the sHASEGP is a human sHASEGP.

115. The method of claim 114, wherein the human sHASEGP is a PH20 sHASEGP.

116. The method of claim 115, wherein the sHASEGP is a soluble polypeptide as set forth in SEQ ID NO. 4.

117. The method of claim 94, wherein the sHASEGP is a pegylated or super-sialated sHASEGP.

118. The method of claim 116, wherein the sHASEGP is a pegylated human PH20 sHASEGP.

119. A method of ameliorating the consequences of stroke or other CNS injury in a mammal, comprising introducing a sHASEGP into a mammal following said stroke or CNS injury.

124-127. -127. (canceled)

128. A PEGylated hyaluronidase, wherein the hyaluronidase comprises at least about three PEG moieties per polypeptide.

138. A method of delivering a molecule to a tissue containing excess amounts of glycosaminoglycan, comprising:

administering a PEGylated hyaluronidase of claim 128 to a tissue in an amount sufficient to degrade glycosaminoglycans sufficiently to open channels less than about 500 nm in diameter; and

administering a molecule to the tissue comprising the degraded glycosaminoglycans.

139. A pharmaceutical composition, comprising a PEGylated hyaluronidase of claim 128 and a pharmaceutical carrier.

140. A method for increasing the diffusion of a therapeutic substance or other molecule or macromolecular complex (each an Agent) smaller than about 0.5 microns in diameter in a subject, comprising:

administering to a subject a PEGylated hyaluronidase of claim 128 in an amount sufficient to open or to form channels smaller than about 0.5 microns in diameter and an Agent, whereby the diffusion of the Agent is increased.

141. The method of claim 140, wherein the Agent is selected from the group of agents consisting of a chemotherapeutic agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonocidal agent, an anti-parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, an antiarthritics agent, an anti-fungal agent, an antihypertensive agent, an antipyretic agent, an anti-parasitic agent, an antihistamine agent, an alpha-adrenargic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchial dilator agent, a biocide agent, a bactericide agent, a bacteriostatic agent, a beta adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, an electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sleep inducer, a sympathomimetic agent, a tranquilizer agent, a urinary agent, a vaginal agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, an angiotensin converting enzyme inhibitor agent, a polypeptide, a protein, a nucleic acid, a drug, or an organic molecule.

144. A method of inducing liquefaction of vitreous humor to treat a disorder of a mammalian eye comprising contacting the vitreous humor with an amount of a PEGylated hyaluronidase of claim 128 effective to liquefy said vitreous humor whereby the disorder is treated.

129-133. -133. (canceled)

134. A method of preparing a PEGylated hyaluronidase, comprising reacting a hyaluronidase with a molar excess of a PEG reagent selected from the group consisting of a PEG-succinimidyl butanoate, a PEG-succinimidyl methylbutanoate, a PEG-succinimidyl proprionate, a PEG-N-hydroxysuccinimide, a PEG-aldehyde, a PEG-carbonate, a PEG-propionaldehyde and a PEG-maleimide.

135. The method of claim 134 wherein the PEG reagent is selected from the group consisting of mPEG-SBA (5 kDa), mPEG-SBA (20 kDa), mPEG-SBA 30 kDa), mPEG-SMB (20 kDa) MPEG-SMB (30 kDa), mPEG-butyraldehyde (30 kDa), mPEG-SPA (20 kDa), mPEG-SPA (30 kDa), mPEG2-NHS (10 kDa branched), mPEG2-NHS (20 kDa branched), MPEG-NHS (40 kDa branched), mPEG2-NHS (60 kDa branched), PEG-NHS-biotin (5 kDa biotinylated), PEG-p-nitrophenyl-carbonate (30 kDa) and PEG-propionaldehyde (30 kDa).

136. A PEGylated hyaluronidase produced according to the method of claim 134.

137. A PEGylated hyaluronidase produced according to the method of claim 135.

142-143. -143. (canceled)

145-153. -153. (canceled)